Ge Long Hui·2025-12-10 10:29Core Viewpoint - Fosun Pharma's subsidiary, Guilin Pharmaceutical Co., has received approval from the National Medical Products Administration for the registration of Sodium Phosphonacetate Injection, which is indicated for the treatment of AIDS-related cytomegalovirus retinitis and herpes simplex virus skin and mucosal infections in immunocompromised patients [1]. Group 1: Product Details - Product Name: Sodium Phosphonacetate Injection [1] - Dosage Form: Injection [1] - Specification: 250ml:6g (calculated as CNa₃O₅P·6H₂O) [1] - Registration Classification: Class 3 Chemical Drug [1] - Marketing Authorization Holder: Guilin Pharmaceutical Co., Ltd. [1] - Drug Approval Number: National Drug Approval Code H20256094 [1] Group 2: Indications - Approved indications include treatment for (1) cytomegalovirus retinitis in AIDS patients and (2) herpes simplex virus skin and mucosal infections in patients with immune dysfunction [1].